INSTINCT BIO TECHNICAL COMPANY HOLDINGS INC. (Nasdaq: BIOT) announced on September 30, 2026, that CelSiege Biosciences Inc. has appointed it as a non-exclusive authorized introduction and business development representative for IN01, a clinical-stage cancer immunotherapy, in Japan and the People's Republic of China. The appointment, formalized through a Letter of Authorisation signed on September 18, 2026, by CelSiege Founder and Director Johan Indot, allows BIOT to introduce the IN01 Program to potential strategic partners, investors, pharmaceutical and biotechnology companies, medical institutions, research organizations, and investment funds in both countries. BIOT is also authorized to facilitate preliminary discussions on potential investment, licensing, co-development, clinical development, manufacturing, and commercialization. Any definitive transaction would remain subject to separate negotiations, due diligence, and definitive agreements.
The significance of this move lies in its potential to accelerate the development and commercialization of a promising immunotherapy in two of the world's most critical oncology markets. Japan and China together host the largest lung cancer patient populations globally, alongside advanced clinical research capabilities. According to the International Agency for Research on Cancer, lung cancer was the most frequently diagnosed cancer worldwide in 2022, with approximately 2.5 million new cases and 1.8 million deaths. Non-small cell lung cancer (NSCLC) accounts for about 80% to 85% of lung cancer cases, per the American Cancer Society, and Fortune Business Insights estimates the global NSCLC therapeutics market at approximately $38.49 billion in 2025. These figures underscore the immense unmet medical need and the commercial opportunity that a successful new therapy could address.
IN01 is described by CelSiege as an active immunotherapy, or therapeutic cancer vaccine, targeting epidermal growth factor (EGF). It is designed to stimulate the patient's immune system to produce antibodies against circulating EGF, a growth factor involved in the proliferation of certain cancer cells. The lead indication is squamous non-small cell lung cancer, with potential expansion into colorectal, head-and-neck, and other cancers. As a clinical-stage asset, IN01 has not received marketing approval, and its development carries inherent risks. Nonetheless, BIOT's CEO Tomoki Nagano expressed confidence in the program: "We believe IN01 is a promising clinical-stage program in the field of active cancer immunotherapy, and we are fully committed to helping build a path for this science to reach the patients who need it." He added that BIOT will work with a strong sense of ownership to identify partners and pursue collaborations that can advance IN01's development and commercialization.
The appointment extends BIOT's business development activities into clinical-stage oncology, complementing its existing focus on beauty, wellness, regenerative medicine, and related healthcare sectors. CelSiege Biosciences, headquartered in Marseille, France, with operations in the United States, is focused on active immunotherapies and has a proprietary B-cell-mediated platform designed to stimulate polyclonal antibody responses against disease-associated ligands. For more information, visit CelSiege Biosciences. BIOT, a diversified healthcare and biotechnology company, seeks to build an integrated platform connecting innovative healthcare technologies with growth opportunities across Asia and other international markets. Additional details are available at https://instinct-biot.com/. This announcement was originally distributed via NEWMEDIAWIRE.
While the agreement is non-exclusive and any eventual transaction remains uncertain, the appointment positions BIOT to play a pivotal role in bridging CelSiege's innovative immunotherapy with potential partners in two key Asian markets. If successful, it could bring a novel treatment option to lung cancer patients who currently face limited therapeutic choices, while also providing BIOT with a strategic entry into the high-value oncology sector. The coming months will reveal whether BIOT can leverage its regional networks to secure the collaborations needed to propel IN01 through clinical development and toward regulatory approval.
